{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:16:27Z","timestamp":1770718587958,"version":"3.49.0"},"reference-count":57,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014688","name":"Region Uppsala","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Background and aims: One out of three men who undergo cystoprostatectomy for bladder cancer is diagnosed with incidental prostate cancer (PCa) at histopathological examination. Many of these men are PSA tested as part of their follow-up, but it is unclear if this is needed. The aim of this study was to assess the risk of PCa death in these men and the need of PSA-testing during follow-up.\nMethods: Between 2002 and 2020, 1,554 men were diagnosed with PCa after cystoprostatectomy performed for non-metastatic bladder cancer and registered in the National Prostate Cancer Register (NPCR) of Sweden. We assessed their risk of death from PCa, bladder cancer and other causes up to 15 years after diagnosis by use of data in The Cause of Death Register. The use of androgen deprivation therapy (ADT) as a proxy for PCa progression was assessed by fillings in The Prescribed Drug Register.\nResults: Fifteen years after diagnosis, cumulative incidence of death from PCa was 2.6% (95% CI 2.3%\u20132.9%), from bladder cancer 32% (95% CI: 30%\u201334%) and from other causes 40% (95% CI: 36%\u201344%). Only 35% of men with PCa recorded as primary cause of death in The Cause of Death Register had started ADT before date of death, indicating sticky-diagnosis bias with inflated risk of PCa death.\nConclusions: For a large majority of men diagnosed with incidental PCa at cystoprostatectomy performed for bladder cancer, the risk of PCa death is very small so there is no rationale for PSA testing during follow-up.<\/jats:p>","DOI":"10.2340\/sju.v59.40001","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T08:37:34Z","timestamp":1715589454000},"page":"98-103","source":"Crossref","is-referenced-by-count":3,"title":["Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat\u00adectomy. A nationwide population-based study"],"prefix":"10.2340","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6126-9889","authenticated-orcid":false,"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-0370","authenticated-orcid":false,"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-7083","authenticated-orcid":false,"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2783-3542","authenticated-orcid":false,"given":"Andri","family":"Wilberg Orrason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8306-0687","authenticated-orcid":false,"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-6967","authenticated-orcid":false,"given":"Marcus","family":"Westerberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"59645","doi-asserted-by":"crossref","unstructured":"Bell KJL, Del Mar C, Wright G, et al. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137(7):1749\u20131757.","DOI":"10.1002\/ijc.29538"},{"key":"59646","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ijc.29538","DOI":"10.1002\/ijc.29538"},{"key":"59647","doi-asserted-by":"crossref","unstructured":"Fahmy O, Khairul-Asri MG, Schubert T, et al. Clinicopathological features and prognostic value of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: a systematic review and meta-analysis of 13,140 patients. J Urol. 2017;197(2):385\u2013390.","DOI":"10.1016\/j.juro.2016.08.088"},{"key":"59648","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.juro.2016.08.088","DOI":"10.1016\/j.juro.2016.08.088"},{"key":"59649","doi-asserted-by":"crossref","unstructured":"Bruins HM, Djaladat H, Ahmadi H, et al. Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens. J Urol. 2013;190(5):1704\u20131709.","DOI":"10.1016\/j.juro.2013.05.034"},{"key":"59650","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.juro.2013.05.034","DOI":"10.1016\/j.juro.2013.05.034"},{"key":"59651","doi-asserted-by":"crossref","unstructured":"Thomas C, Giesswein A, Hainz M, et al. Concomitant gleason Score \u22657 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy. Int Urol Nephrol. 2015;47(11):1789\u20131796.","DOI":"10.1007\/s11255-015-1110-1"},{"key":"59652","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11255-015-1110-1","DOI":"10.1007\/s11255-015-1110-1"},{"key":"59653","doi-asserted-by":"crossref","unstructured":"Heidegger I, Oberaigner W, Horninger W, et al. High incidence of clinically significant concomitant prostate cancer in patients undergoing radical cystectomy for bladder cancer: a 10-year single-center experience. Urol Oncol. 2017;35(4):152.e1\u20135.","DOI":"10.1016\/j.urolonc.2016.11.004"},{"key":"59654","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.11.004","DOI":"10.1016\/j.urolonc.2016.11.004"},{"key":"59655","doi-asserted-by":"crossref","unstructured":"Liedberg F, Kjellstr\u00f6m S, Lind AK, et al. Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. Scand J Urol. 2022;56(2):137\u2013146.","DOI":"10.1080\/21681805.2022.2041086"},{"key":"59656","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2041086","DOI":"10.1080\/21681805.2022.2041086"},{"key":"59657","doi-asserted-by":"crossref","unstructured":"Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265\u2013273.","DOI":"10.1080\/21681805.2022.2094462"},{"key":"59658","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2094462","DOI":"10.1080\/21681805.2022.2094462"},{"key":"59659","doi-asserted-by":"crossref","unstructured":"Bratt O, Carlsson S, Fransson P-A, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration-resistant disease. Scand J Urol. 2022;56(4):278\u2013284.","DOI":"10.1080\/21681805.2022.2093396"},{"key":"59660","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2093396","DOI":"10.1080\/21681805.2022.2093396"},{"key":"59661","doi-asserted-by":"crossref","unstructured":"Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base\u2014a refined prostate cancer trajectory. Int J Epidemiol. 2015;45(1):73\u201382.","DOI":"10.1093\/ije\/dyv305"},{"key":"59662","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ije\/dyv305","DOI":"10.1093\/ije\/dyv305"},{"key":"59663","doi-asserted-by":"crossref","unstructured":"Tomi\u0107 K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101\u2013111.","DOI":"10.1016\/j.ejca.2014.10.025"},{"key":"59664","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2014.10.025","DOI":"10.1016\/j.ejca.2014.10.025"},{"key":"59665","doi-asserted-by":"crossref","unstructured":"Tomi\u0107 K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2014;54(2):158\u2013163.","DOI":"10.3109\/0284186X.2014.939299"},{"key":"59666","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/0284186X.2014.939299","DOI":"10.3109\/0284186X.2014.939299"},{"key":"59667","doi-asserted-by":"crossref","unstructured":"Ludvigsson JF, Appelros P, Askling J, et al. Adaptation of the Charlson Comorbidity Index for register-based research in Sweden. Clin Epidemiol. 2021;13:21\u201341.","DOI":"10.2147\/CLEP.S282475"},{"key":"59668","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S282475","DOI":"10.2147\/CLEP.S282475"},{"key":"59669","unstructured":"R Core Team. R: A language and environment for statistical computing [Internet]. R Foundation for Statistical Computing, Vienna, Austria; 2022. [cited 14-12-2023] Available from: https:\/\/www.R-project.org\/"},{"key":"59670","unstructured":"Svenska Nationella Kvalitetsregistret f\u00f6r urinbl\u00e5se-och urinv\u00e4gscancer (SNRUBC). SNRUBC [Internet]. 2023 [cited 14-12-2023]. Available from: https:\/\/statistik.incanet.se\/Urinblasecancer\/"},{"key":"59671","unstructured":"Cancerregistret. Socialstyrelsen [Internet]. 2023 [cited 14-12-2023]. Available from: https:\/\/www.socialstyrelsen.se\/statistik-och-data\/register\/cancerregistret\/"},{"key":"59672","doi-asserted-by":"crossref","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):450.","DOI":"10.1186\/1471-2458-11-450"},{"key":"59673","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1471-2458-11-450","DOI":"10.1186\/1471-2458-11-450"},{"key":"59674","doi-asserted-by":"crossref","unstructured":"Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register \u2013 a sample survey for year 1998. Acta Oncol. 2009;48(1):27\u201333.","DOI":"10.1080\/02841860802247664"},{"key":"59675","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/02841860802247664","DOI":"10.1080\/02841860802247664"},{"key":"59676","doi-asserted-by":"crossref","unstructured":"Fall K, Str\u00f6mberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42(4):352\u2013357.","DOI":"10.1080\/00365590802078583"},{"key":"59677","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/00365590802078583","DOI":"10.1080\/00365590802078583"},{"key":"59678","doi-asserted-by":"crossref","unstructured":"Godtman R, Holmberg E, Stranne J, et al. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: acomparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol. 2011;45(4):226\u2013232.","DOI":"10.3109\/00365599.2011.559950"},{"key":"59679","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/00365590802078583","DOI":"10.1080\/00365590802078583"},{"key":"59680","doi-asserted-by":"crossref","unstructured":"Pignot G, Salomon L, Neuzillet Y, et al. Clinicopathological characteristics of incidental prostate cancer discovered from radical cystoprostatectomy specimen: a multicenter French study. Ann Surg Oncol. 2013;21(2):684\u2013690.","DOI":"10.1245\/s10434-013-3340-8"},{"key":"59681","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1245\/s10434-013-3340-8","DOI":"10.1245\/s10434-013-3340-8"},{"key":"59682","doi-asserted-by":"crossref","unstructured":"Packiam VT, Tsivian M, Avulova S, et al. Long-term outcomes of incidental prostate cancer at radical cystectomy. Urol Oncol. 2020;38(11):848.e17\u201322.","DOI":"10.1016\/j.urolonc.2020.05.018"},{"key":"59683","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.018","DOI":"10.1016\/j.urolonc.2020.05.018"},{"key":"59684","doi-asserted-by":"crossref","unstructured":"Liedberg F, Anderson H, Bl\u00e4ckberg M, et al. Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen. Scand J Urol Nephrol. 2007;41(4):290\u2013296.","DOI":"10.1080\/00365590601183576"},{"key":"59685","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/00365590601183576","DOI":"10.1080\/00365590601183576"},{"key":"59686","doi-asserted-by":"crossref","unstructured":"Kimura T, Sato S, Takahashi H, et al. Global trends of latent prostate cancer in autopsy studies. Cancers. 2021;13(2):359.","DOI":"10.3390\/cancers13020359"},{"key":"59687","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers13020359","DOI":"10.3390\/cancers13020359"},{"key":"59688","doi-asserted-by":"crossref","unstructured":"Bergengren O, Westerberg M. Watch out for sticky diagnosis bias in older men with prostate cancer. Scand J Urol. 2022;56(5\u20136):365\u2013366.","DOI":"10.1080\/21681805.2022.2124305"},{"key":"59689","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2124305","DOI":"10.1080\/21681805.2022.2124305"},{"key":"59690","doi-asserted-by":"crossref","unstructured":"Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2023;131(4):486\u2013493.","DOI":"10.1111\/bju.15891"},{"key":"59691","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.15891","DOI":"10.1111\/bju.15891"},{"key":"59692","doi-asserted-by":"crossref","unstructured":"L\u00f6ffeler S, Halland A, Weedon-Fekj\u00e6r H, et al. High Norwegian prostate cancer mortality: evidence of over-reporting. Scand J Urol. 2018;52(2):122\u2013128.","DOI":"10.1080\/21681805.2017.1421260"},{"key":"59693","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2017.1421260","DOI":"10.1080\/21681805.2017.1421260"},{"key":"59694","doi-asserted-by":"crossref","unstructured":"Innos K, Paapsi K, Alas I, et al. Evidence of overestimating prostate cancer mortality in Estonia: a population-based study. Scand J Urol. 2022;56(5\u20136):359\u2013364.","DOI":"10.1080\/21681805.2022.2119274"},{"key":"59695","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2119274","DOI":"10.1080\/21681805.2022.2119274"},{"key":"59696","doi-asserted-by":"crossref","unstructured":"Lycken M, Drevin L, Garmo H, et al. The use of palliative medications before death from prostate cancer: a Swedish population-based study with a comparative overview of European data. Eur J Cancer. 2018;88:101\u2013108.","DOI":"10.1016\/j.ejca.2017.10.023"},{"key":"59697","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.023","DOI":"10.1016\/j.ejca.2017.10.023"},{"key":"59698","doi-asserted-by":"crossref","unstructured":"Thomsen FB, Garmo H, Brasso K, et al. Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. J Surg Oncol. 2021;124(5):867\u2013875.","DOI":"10.1002\/jso.26579"},{"key":"59699","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/jso.26579","DOI":"10.1002\/jso.26579"},{"key":"59700","doi-asserted-by":"crossref","unstructured":"van den Bergh RCN, van Casteren NJ, van den Broeck T, et al. Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review. Eur Urol. 2016;69(5):802\u2013820.","DOI":"10.1016\/j.eururo.2015.11.023"},{"key":"59701","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2015.11.023","DOI":"10.1016\/j.eururo.2015.11.023"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/40001\/46086","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/40001\/46086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T08:38:09Z","timestamp":1715589489000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/40001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":57,"URL":"https:\/\/doi.org\/10.2340\/sju.v59.40001","relation":{},"ISSN":["2168-1813","2168-1805"],"issn-type":[{"value":"2168-1813","type":"electronic"},{"value":"2168-1805","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}